Evaluate and Understand Preferences and Representations in Families of Patients With Regard to High-throughput Sequencing Technology for Diagnostic Purposes

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

530 participants

Study Classification

INTERVENTIONAL

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

After the use of DNA chips for diagnostic purposes, high-throughput sequencing (HTS) is transforming the field of developmental diseases, from fundamental research to care. Nonetheless, before HTS can be transferred to everyday clinical practice, in particular for expert diagnosis using exome HTS, it is necessary to anticipate the nature of the information to be given to patients and to parents in order to obtain consent for exome HTS.

The objective in terms of public health is to allow patients with rare diseases to benefit from innovative technologies in optimal conditions of information and accompaniment.

the objectives of this project are to

1. evaluate the preferences of families of patients with development disorders as regard to suspicious and incidental findings from HTS before its introduction for diagnostic purpose,
2. and then, following the exome analyses carried out for diagnostic purposes, describe, analyse and understand the experience, expectations and reactions of families and geneticists concerning the diagnostic trajectory in general and at the time the results of the HTS were announced in particular A methodology that associated quantitative and qualitative approaches was chosen so as to combine the advantages and overcome the shortcomings of each: a quantitative study to investigate a large number of patients, which would ensure a certain representativeness of the population and allow sub-groups analyses to study the upstream phase concerning indications for high-throughput sequencing; and a qualitative study, which though it allows only a small number of patients to be investigated, makes it possible to describe, analyze and understand in depth the complex downstream phenomena of high-throughput sequencing results

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Contribution of High-throughput Exome Sequencing in the Diagnosis of the Cause Fetal Polymalformation Syndromes

NCT02512354

Fetuses With at Least 2 Malformations, and no Diagnosis After Fetopathological and Radiological Examinations

COMPLETED

Characterization and Contribution of Genome-wide DNA Methylation (DNA Methylation Episignatures) in Rare Diseases With Prenatal Onset

NCT06475651

Rare Fetal Genetic Diseases Congenital Malformation

NOT_YET_RECRUITING

Study of the Diagnostic Value of "Rapid" High Throughput Genome Sequencing Analysis in Diagnostic Emergency Situations

NCT03956069

Developmental Anomalies

COMPLETED

Transcriptomic Approach for the Identification and Prioritization of Genome Variants in Neurodevelopmental Disorders With Malformation

NCT06762678

Neurodevelopmental Disorders and Developmental Abnormalities

NOT_YET_RECRUITING NA

Evaluation of Rapid First-line Genome Sequencing for Prenatal Diagnosis of Congenital Malformations in Comparison With Chromosomal Microarray and Exome Sequencing

NCT06252415

Congenital Malformation

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rare Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

PARALLEL

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

quantitive study: 500 patients likely to be candidates for HTS

quantitive study: 500 patients likely to be candidates for HTS at CR in Dijon and Lyon, that is to say patients with development anomalies and/or intellectual deficiency with no etiological diagnosis.

Group Type EXPERIMENTAL

quantitive study: 500 patients likely to be candidates for HTS

Intervention Type OTHER

qualitative study: 30 patients who have benefited from HTS and

qualitative study: 30 patients who have benefited from HTS and the medical geneticists who accompanied them in this approach.

Group Type EXPERIMENTAL

qualitative study: 30 patients who have benefited from HTS

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

quantitive study: 500 patients likely to be candidates for HTS

Intervention Type OTHER

qualitative study: 30 patients who have benefited from HTS

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* parents of patients with development anomaly and/or intellectual deficiency with no etiological diagnosis
* parents of patients consulting at the centres of reference in Dijon or Lyon
* parents of patients who have not already benefited from HTS
* parents of patients who are fluent in French

* persons without national health insurance cover
* inability to answer the questionnaires

Qualitative study

* persons who have provided written informed consent
* parents of patients with a development anomaly
* parents of patients consulting at the centres of reference in Dijon or Lyon
* parents of patients who have already benefited from HTS for diagnostic purposes
* persons fluent in French

* persons without national health insurance cover
* cognitive impairment making it impossible for the person to understand the aims of the study

Eligible Sex

ALL

Accepts Healthy Volunteers

No